Impact of sonelokimab, an IL-17A/F-inhibiting Nanobody, on clinical and imaging outcomes in axial spondyloarthritis: Results of a Phase 2 study supported by 18F-NaF PET imaging and MRI

sonelokimab (M1095) - Avillion, MoonLake Immunotherap

https://distribution-congress.eular.org/from.storage?image=15rRXWmdOAJ77zPlkD-rQn6yndzGyk7lDHOgt0xDIqJM8d5fDfeOF-yuzgUc6ffh0

Brikena Lalazi1, 2; Uta Kiltz1, 2; Philipp Sewerin1, 2; Hubertus Hautzel3; Andreas Ramming4; Roman Akbar-Haase5; Valerie Millar5; Mahesh Nadimpalli5; Matthew R. Thomas5; Ana Pereira5; Eva Cullen5; Kristian Reich5, 6; Xenofon Baraliakos1, 2

May 5, 2026